Overview

Effectiveness and Tolerance of Inhaled Fentanyl Aerosol (25µg/Dose) in Chinese Patients With Breakthrough Cancer Pain

Status:
Not yet recruiting

Trial end date:
2021-12-21

Target enrollment:

Participant gender:

Summary

Breakthrough cancer pain (BTcP) is a common problem in patients with cancer. This is a phase I/IIa, pharmacokinetic, dose-response and safety study of inhaled fentanyl aerosol (25µg/dose) in Chinese patients with breakthrough cancer pain. The study will include two stages.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Lee's Pharmaceutical Limited

Treatments:

Fentanyl